Sym023 not checked
Servier Bio-Innovation LLC · Symphogen A/S · S095018 · Anti-TIM-3
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Non-small Cell Lung Cancer (NSCLC)
- Main trialPhase 1/2
- “This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of…”In the company’s words, NCT06162572 on ClinicalTrials.gov
- Other names
- S095018 · Anti-TIM-3 · S095018 Recommended
Other drugs for Non-small Cell Lung Cancer (NSCLC)
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up1
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Apr 2027 | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | |
| Phase 1Completed | 3 Jun 2020 | Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | |
| Phase 1Completed | 23 Mar 2022 | Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas | |
| Phase 1Completed | 3 Jun 2024 | Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026